Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 References

PF-03654746

●Српски / srpski ●Srpskohrvatski / српскохрватски Edit links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version In other projects ●Wikimedia Commons Appearance From Wikipedia, the free encyclopedia

PF-03654746
Identifiers

IUPAC name trans-N-Ethyl-3-fluoro-3-[3-fluoro-4-(1-pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide
CAS Number	935840-31-6^Y
PubChem CID	16119086
ChemSpider	25069700
UNII	G3QE979K1X
Chemical and physical data
Formula	C₁₈H₂₄F₂N₂O
Molar mass	322.400 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCNC(=O)[C@H]1C[C@@](C1)(F)C2=CC(=C(C=C2)CN3CCCC3)F
InChI InChI=1S/C18H24F2N2O/c1-2-21-17(23)14-10-18(20,11-14)15-6-5-13(16(19)9-15)12-22-7-3-4-8-22/h5-6,9,14H,2-4,7-8,10-12H2,1H3,(H,21,23)/t14-,18- Key:SXMBKHYDZOCBMT-PPUGGXLSSA-N
(verify)

PF-03654746 is a potent and selective histamine H₃ receptor antagonist developed by Pfizer and currently undergoing clinical trials for the treatment of ADHD, Tourette syndrome^[1] as well as potential anti-allergy applications.^[2]^[3]^[4]^[5]

References[edit]

^ Clinical trial number NCT01475383 for "Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome" at ClinicalTrials.gov

^ Soares H, Wager TT, Schmidt AW, Sweeney FJ, McLellan TJ, Nelson FR, Spracklin D, Wang EQ, Faessel H, Pinter GW, Li X (2010). "The Effects of an H3 Receptor Antagonist in a Nasal Allergen Challenge Model". Journal of Allergy and Clinical Immunology. 125 (2): AB191. doi:10.1016/j.jaci.2009.12.750.

^ "H3 receptor antagonism increases methylhistamine levels in the cerebrospinal fluid of dogs and healthy human volunteers". Alzheimer's & Dementia. 5 (4): P254. doi:10.1016/j.jalz.2009.04.272. S2CID 54316270.

^ Gemkow MJ, Davenport AJ, Harich S, Ellenbroek BA, Cesura A, Hallett D (May 2009). "The histamine H3 receptor as a therapeutic drug target for CNS disorders". Drug Discovery Today. 14 (9–10): 509–15. doi:10.1016/j.drudis.2009.02.011. PMID 19429511.

^ Wijtmans M, Denonne F, Célanire S, Gillard M, Hulscher S, Delaunoy C, Bakker RA, Defays S, Gérard J, Grooters L, Hubert D (2010). "Histamine H3 receptor ligands with a 3-cyclobutoxy motif: a novel and versatile constraint of the classical 3-propoxy linker". MedChemComm. 1: 39. doi:10.1039/c0md00056f.